- Home
- WIMI vs KPRX Comparison
WIMI vs KPRX Comparison
Compare WIMI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIMI | KPRX |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.6M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WIMI | KPRX |
|---|---|---|
| Price | $0.61 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 156.4K | 11.8K |
| Earning Date | 12-18-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $211.95 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $1.76 |
| 52 Week High | $4.16 | $2.91 |
Technical Indicators
Market Signals| Indicator | WIMI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 30.30 |
| Support Level | N/A | $2.28 |
| Resistance Level | $1.43 | $2.72 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 44.35 | 0.00 |
Price Performance
Historical ComparisonAbout WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.